The early 2017/18 influenza season in Europe was characterised by co-circulation of influenza B, A(H3N2) and A(H1N1)pdm09, with lineage mismatched influenza B(Yamagata) virus predominating in many countries \[[@r1],[@r2]\]. Concerns arose due to the low influenza vaccine effectiveness (VE) reported in the 2017 influenza A(H3N2) epidemic in Australia \[[@r3]\] and the warning about low VE of the trivalent influenza vaccine (TIV) against a lineage mismatched influenza B(Yamagata) virus \[[@r4]\]. Influenza vaccination in previous seasons may retain some preventive effect and modify the effect of the current season vaccination so the vaccination history should be considered in the VE assessment \[[@r5],[@r6]\].

We present the 2017/18 interim effectiveness estimates of different combinations of current and prior season influenza vaccination in preventing laboratory-confirmed influenza.

Study design and information sources
====================================

A test-negative case--control study was used for the estimations. Cases and controls were identified through the influenza epidemiological and virological surveillance in primary healthcare and hospitals in Navarre, northern Spain. In October and November 2017, the trivalent inactivated non-adjuvanted vaccine was offered free of charge to the target population for vaccination, which included people aged 60 years or more and people with major chronic conditions. The TIV comprised influenza A/Michigan/45/2015(H1N1)-like, A/HongKong/4801/2014(H3N2)-like and B/Brisbane/60/2008(Victoria-lineage)-like antigens \[[@r7]\]. The TIV had contained B(Yamagata) antigens in the 2012/13 to 2015/16 seasons \[[@r8]\]. Influenza vaccine status in the current and five prior influenza seasons, 2012/13 to 2017/18, was obtained from the regional vaccination register, where all vaccines administered in healthcare centres are registered online \[[@r9]\]. Persons were considered to be protected by the vaccine 14 days after receiving it.

Influenza surveillance relied on all primary healthcare physicians and hospitals automatically reporting influenza-like illness (ILI) cases \[[@r6]\]. A sentinel network of primary healthcare physicians collected nasopharyngeal and pharyngeal swabs from their patients diagnosed with ILI, when symptoms had appeared less than five days before. In hospitals, early detection and swabbing of all hospitalised patients with ILI was specified by the protocol. Samples were processed by reverse-transcription PCR assay. A selection of representative strains of each week and virus type/subtype was sent to the National Influenza Centre--Madrid laboratory to be completely genetically characterised.

Statistical analysis
====================

The study population included individuals covered by the Navarre Health Service since 2012 (96% of the population). All ILI patients who were swabbed in December 2017 and January 2018 were considered. We excluded healthcare workers, people living in nursing homes, children under 9 years of age and patients hospitalised prior to ILI symptom onset. The seasonal vaccination status of patients testing positive for influenza virus (cases) was compared to that of those who were negative for this virus (controls). Logistic regression models were employed to derive crude and adjusted odds ratios (OR) with their 95% confidence intervals (CI). Adjusted models included sex, age group (9--24, 25--44, 45--64, 65--84 and ≥ 85 years), major chronic conditions, month of swabbing and healthcare setting. Four categories combining the current-season and five prior season vaccination were considered: current-season vaccination and any prior doses, current-season vaccination and no prior doses, no current-season vaccination and any prior doses, and no current-season vaccination and no prior doses (reference group). VE was estimated as a percentage: (1 -- OR) x 100.

Influenza vaccine effectiveness interim estimation
==================================================

A total of 1,268 ILI patients were included, 808 (64%) inpatients and 460 (36%) primary healthcare patients. A total of 654 (52%) were confirmed cases for influenza virus: 498 (76%) for influenza B, 118 (18%) for A(H3N2), 36 (6%) for A(H1N1)pdm09 and two non-subtyped influenza A viruses.

The sequence derived from the amplification product of the HA1 fragment of the haemagglutinin gene was characterised for 51 viruses. Of 40 influenza B viruses, 35 were B/Phuket/3073/2013(Yamagata-lineage)-like, three B/Brisbane/60/2008(Victoria-lineage)-like and two B/Norway/2409/2017(Victoria-lineage)-like. The four A(H1N1)pdm09 strains were A/Michigan/45/2015-like. Among seven A(H3N2) strains, five were A/HongKong/4801/2014-like and two A/Singapore/16--0019/2016-like.

Compared with test-negative controls, influenza cases comprised a lower proportion of individuals aged 65 years or older, of persons with comorbidities or who were attended in hospitals. Among cases, 35% (231/654) had been vaccinated in the 2017/18 season vs 54% (331/614) among controls (p \< 0.001) ([Table 1](#t1){ref-type="table"}).

###### Characteristics of the patients with medically-attended influenza-like illness included in the test-negative case--control analysis, Navarre, Spain, December 2017--January 2018 (n = 1,268 patients)

  Characteristics                       Test-negative controls   All influenza cases   Influenza B   Influenza A(H3N2)   Influenza A(H1N1)pdm09                                          
  ------------------------------------- ------------------------ --------------------- ------------- ------------------- ------------------------ --------- --------- --------- -------- ---------
  **Age groups (years)**                                                                                                                                                                 
  9--24                                 14                       2                     35            5                   30                       6         2         2         3        8
  25--44                                89                       15                    150           23                  109                      22        27        22        14       39
  45--64                                123                      20                    170           26                  136                      27        25        21        8        22
  65--84                                271                      44                    203           31                  158                      32        37        32        8        22
  ≥ 85                                  117                      19                    96            15                  65                       13        27        23        3        8
  **Sex**                                                                                                                                                                                
  Male                                  336                      55                    311           48                  230                      46        62        52        18       50
  Female                                278                      45                    343           52                  268                      54        56        48        18       50
  **Major chronic conditions**                                                                                                                                                           
  No                                    167                      27                    278           43                  221                      44        37        31        19       53
  Yes                                   447                      73                    376           57                  277                      56        80        69        17       47
  **Month of swabbing**                                                                                                                                                                  
  December                              178                      29                    91            14                  76                       15        11        9         4        11
  January                               436                      71                    563           86                  422                      85        107       91        32       89
  **Target group for vaccination^a^**                                                                                                                                                    
  No                                    110                      18                    210           32                  164                      33        27        23        18       50
  Yes                                   504                      82                    444           68                  334                      67        91        77        18       50
  **Healthcare setting**                                                                                                                                                                 
  Primary healthcare                    131                      21                    329           50                  264                      53        43        37        22       61
  Hospitalization                       483                      79                    325           50                  234                      47        75        63        14       39
  **2017/18 season vaccine**                                                                                                                                                             
  No                                    283                      46                    423           65                  328                      66        66        56        28       78
  Yes                                   331                      54                    231           35                  170                      34        52        44        8        22
  **Total**                             **614**                  **100**               **654**       **100^b^**          **498**                  **100**   **118**   **100**   **36**   **100**

^a^ Target group for vaccination includes people ≥ 60 years-old and people with major chronic conditions.

^b^ Two cases were influenza A not subtyped.

Regardless of the vaccination history, the overall adjusted estimate of influenza VE was 39% (95% CI: 20 to 54). In persons less than 65 years-old the estimates were higher (55%) than in the older age group (30%), and in outpatients (51%) than inpatients (35%). VE was 41% (95% CI: 20 to 56) against influenza B, 29% (95% CI: --15 to 57) against A(H3N2), and 59% (95% CI: --6 to 84) against A(H1N1)pdm09 ([Table 2](#t2){ref-type="table"}).

###### Influenza vaccine effectiveness in preventing laboratory-confirmed influenza among individuals aged 9 years or older in Navarre, Spain, December 2017--January 2018 (n = 1,268 patients)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Models                                Controls\                 Cases\                    Crude vaccine effectiveness\   Adjusted vaccine effectiveness\
                                        Vaccinated/unvaccinated   Vaccinated/unvaccinated   % (95% CI)                     % (95% CI)^a^
  ------------------------------------- ------------------------- ------------------------- ------------------------------ ---------------------------------
  **All swabbed patients**              331/283                   231/423                   53 (42 to 63)                  39 (20 to 54)

  **Target group for vaccination^b^**   318/186                   216/228                   45 (28 to 57)                  39 (17 to 54)

  **Age group**                                                                                                            

  9--64 years                           54/172                    41/314                    58 (35 to 73)                  55 (26 to 73)

  ≥ 65 years                            277/111                   190/109                   30 (4 to 49)                   30 (2 to 50)

  **Virus type/subtype**                                                                                                   

  Influenza B                           331/283                   170/328                   56 (43 to 65)                  41 (20 to 56)

  Influenza A(H3N2)                     331/283                   52/66                     33 (0 to 55)                   29 (--15 to 57)

  Influenza A(H1N1)pdm09                331/283                   8/28                      76 (46 to 89)                  59 (--6 to 84)

  **Primary healthcare patients**                                                                                          

  All influenza viruses                 35/96                     56/273                    44 (9 to 65)                   51 (13 to 73)

  Influenza B                           35/96                     47/217                    41 (2 to 64)                   52 (12 to 74)

  Influenza A(H3N2)                     35/96                     6/37                      56 (--14 to 83)                54 (--44 to 85)

  Influenza A(H1N1)pdm09                35/96                     3/19                      57 (--55 to 88)                49 (--120 to 88)

  **Hospitalised patients**                                                                                                

  All influenza viruses                 296/187                   175/150                   26 (2 to 45)                   35 (11 to 53)

  Influenza B                           296/187                   123/111                   30 (4 to 49)                   37 (11 to 55)

  Influenza A(H3N2)                     296/187                   46/29                     0 (--65 to 39)                 20 (--40 to 54)

  Influenza A(H1N1)pdm09                296/187                   5/9                       65 (--6 to 88)                 63 (--27 to 89)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval.

**^a^** Logistic regression model adjusted for sex, age group (9--24, 25--44, 45--64, 65--85 and ≥ 85 years), major chronic conditions, month of swabbing and healthcare setting (primary healthcare and hospital).

^b^ Target group for vaccination includes people ≥ 60 years old and people with major chronic conditions.

Nevertheless, better levels of protection were observed in the analysis considering the vaccination history. Compared with persons never vaccinated in the current and five previous seasons, the preventive effect was 42% (95% CI: 20 to 58) in those vaccinated in the current and any prior seasons, 65% (95% CI: 32 to 82) in those vaccinated only in the current season, and 28% (95% CI: --11 to 53) in those vaccinated only in any prior seasons. The corresponding estimates against influenza B were 41% (95% CI: 17 to 59), 67% (95% CI: 31 to 84) and 22% (95% CI: --24 to 51), and against A(H3N2) were 43% (95% CI: --1 to 67), 51% (95% CI: --51 to 84) and 54% (95% CI: --7 to 80), respectively ([Table 3](#t3){ref-type="table"}).

###### Effectiveness of current season influenza vaccination and of vaccination in the five prior seasons in preventing laboratory-confirmed influenza cases among people aged 9 years or older, Navarre, Spain, December 2017--January 2018 (n = 1,268 patients)

  ----------------------------------------------------------------------------------------------------------------------------------------
  Vaccination history by type of patients or influenza   Cases/controls   Crude vaccine effectiveness\   Adjusted vaccine effectiveness\
                                                                          % (95% CI)                     % (95% CI)^a^
  ------------------------------------------------------ ---------------- ------------------------------ ---------------------------------
  **All patients**                                                                                       

  Never vaccinated                                       366/211          Reference                      Reference

  No current + any prior dose                            57/72            54 (33 to 69)                  28 (--11 to 53)

  Current only                                           17/28            65 (35 to 81)                  65 (32 to 82)

  Current + any prior dose                               214/303          59 (48 to 68)                  42 (20 to 58)

  **Primary healthcare patients**                                                                        

  Never vaccinated                                       261/87           Reference                      Reference

  No current + any prior dose                            12/9             56 (--9 to 82)                 51 (--25 to 81)

  Current only                                           8/11             76 (38 to 91)                  79 (42 to 92)

  Current + any prior dose                               48/24            33 (--15 to 61)                39 (--20 to 69)

  **Hospitalised patients**                                                                              

  Never vaccinated                                       105/124          Reference                      Reference

  No current + any prior dose                            45/63            16 (--34 to 47)                20 (--31 to 52)

  Current only                                           9/17             38 (--46 to 73)                47 (--28 to 78)

  Current + any prior dose                               166/279          30 (3 to 49)                   41 (13 to 59)

  **Influenza B**                                                                                        

  Never vaccinated                                       283/211          Reference                      Reference

  No current + any prior dose                            45/72            53 (30 to 69)                  22 (--24 to 51)

  Current only                                           13/28            65 (32 to 83)                  67 (31 to 84)

  Current + any prior dose                               157/303          61 (50 to 70)                  41 (17 to 59)

  **Influenza A(H3N2)**                                                                                  

  Never vaccinated                                       28/211           Reference                      Reference

  No current + any prior dose                            8/72             60 (11 to 82)                  54 (--7 to 80)

  Current only                                           4/28             48 (--54 to 83)                51 (--51 to 84)

  Current + any prior dose                               48/303           42 (11 to 82)                  43 (--1 to 67)
  ----------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval.

^a^ Vaccine effectiveness adjusted by age groups (9--24, 25--44, 45--64, 65--84 and ≥ 85 years), sex, major chronic conditions, healthcare setting (primary healthcare and hospital), and month of swabbing.

Discussion
==========

These results suggest a protective effect of the TIV of 42% to 65% in the early 2017/18 season in Navarre, depending on the vaccination status in prior seasons. Moderate VE was observed against influenza B, A(H1N1)pdm09 and A(H3N2).

Our results on influenza B are consistent with those recently reported from Canada \[[@r10]\] and contrast with the low VE expected in a season dominated by lineage mismatched influenza B virus \[[@r4]\]. Although we observed some preventive effect of previous vaccinations in individuals unvaccinated in the current season, the highest VE against influenza B was seen in people vaccinated in the current season but not vaccinated in prior ones, ruling out the possibility that the observed VE is due to the residual effect of previous vaccines containing B(Yamagata). Instead, this notable effectiveness of the TIV against influenza B suggests important cross-lineage protection \[[@r10]-[@r15]\].

The moderate VE against influenza A(H3N2) observed in the analysis adjusted for vaccination history contrasts with the lower estimate from the analysis that only considers current season vaccination, indicating that the vaccination history may be a confounding factor \[[@r6]\]. By including in the analyses any vaccination in the five prior seasons, the reference category was not affected by residual vaccine effect.

Our results from two independent groups, i.e. hospitalised patients and primary healthcare patients, were broadly consistent. The lower point estimates among inpatients in some analyses might be explained by the poorer immune response of patients who required hospitalisation.

This study has some limitations. The number of influenza B cases with known lineage was too small to obtain estimates by lineage, although 88% of known lineages were Yamagata. The results are preliminary and for some analyses, the statistical power is limited. Nevertheless, selection bias was reduced by recruiting laboratory-confirmed cases and controls in the same settings before either patient or physician was aware of laboratory results \[[@r16]\]. We also included outpatients and inpatients, thus obtaining broad representation of patients with influenza. The analyses were adjusted for the healthcare setting as this variable could have acted as a confounding factor.

In conclusion, these results suggest moderate effectiveness of the trivalent inactivated influenza vaccine against the three circulating viruses in the early 2017/18 season in northern Spain. The TIV effectiveness against influenza B suggests an important cross-lineage protection.
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